Agenda: Wednesday, September 11

PHYSICIANS-IN-TRAINING BOOTCAMP

DIDACTIC GENERAL SESSION

STATION 1
Point-of-Care Echocardiography

STATION 2
Radiography: VQ & CTPA

STATION 3
DVT: Diagnosis, Management, Point-of-Care Compression Ultrasound

STATION 4
ICU Cases

STATION 5
Percutaneous Treatment

BPA-CTEPH ALLIANCE CONFERENCE

Welcome

Accessing the CTEPH patient for Balloon Pulmonary Angioplasty
CTEPH Overview
Transition from acute to chronic CTE disease: Lesions that are amenable to BPA

Technical Considerations…Not as Easy as it Looks
Is there a “standard” approach?

Minimizing Risks and Managing complications

What are the Outcomes to measure after the Intervention…and When?

BPA vs PH Targeted Medical Therapy for Inoperable CTEPH… A False Narrative?

Special Patient Groups:
Proximal vessel CTEPH
CTEPD
Post PTE surgery

Future Directions: What more is there to learn?

Closing Remarks

ANNUAL BUSINESS MEETING

Agenda: Thursday, September 12
BREAKFAST & INDUSTRY SATELLITE SESSIONS

SESSION 1: Welcome and Keynote

SESSION 2: Epidemiology Session
  • The Worldwide Weight of VTE: Incidence, Management, and Economic Costs
  • Bridging Borders: Collaborative Strategies to Combat the Global VTE Crisis
  • Evolving Paradigms in PE Riskmanagement: A Dual Focus on Recurrence and Bleeding
  • Equity in Thrombosis: Tackling Disparities in Pulmonary Embolism Treatment
  • Panel discussion

SESSION 3: Diagnosis & Risk Stratification
  • Case presentation
  • Navigating the Currents: Today’s Landscape in PE risk stratification
  • Pro: Risk Stratification for PE: Current Algorithms Fulfill Clinical Needs
  • Con: Revamping Risk Stratifcation: The Urgent Need for Improved PE Algorithm
  • Panel Discussion (Rapid fire questions in risk stratifcation, Audience questions)

SESSION 4: The times they are a-changin’ …Novel Paradigms for Identifying and Treating High Risk PE
  • What do the latest data tell us about High Risk PE and what is missing
  • Identifying “true” High Risk PE … A Tale of Three Patients
  • Debate & Case Presentiation – “Hi-Risk PERT Alert: It’s a Bad One!!"
  • Time Is of the Essence… Push That Bolus!!!
  • Let’s Cool Off with ECMO… Stabilize the Situation!
  • C’mon Folks, Get with the Program…Catheter-directed Therapy Now Reigns Supreme
  • Surgical Embolectomy…Still Forgotten?
  • Discussion and Debate

LUNCH AND INDUSTRY SATELLITE SESSIONS

SESSION 5: Tools of the Trade for Thrombus Resolution: A Decade of PERT
  • The Devil We Know: State of the State: Contemporary Trends in Device Selection Based on Utilization Data
  • The Devil We Don't Know: Limitations in Current Knowledge Base about Devices and Outcomes
  • Debate & Case Presentiation: How I Devour My Clot!: The Challenge of Device Selection
  • Keep it Simple: Just Thin It!
  • Dissovle to Resolve
  • Slice, Dice, & Lyse
  • Aspirate
  • Discussion and Debate

WORKSHOP A: ICU
  • Medical management of the failing RV after PE
  • Don’t intubate the critically ill PE patient!!! But when you have to…
  • Bedside initiation of mechanical RV support
  • Managing complications of catheter-based therapy in the ICU
  • Discussion
WORKSHOP B: VENOUS DISEASE
  • IVC Filters
  • Deep Vein Thrombosis: Medical vs Endovascular
  • Post-Thrombotic Syndrome
  • Endovascular Treatment of Chronic Occlusion
  • Panel
WORKSHOP C: STARTING & GROWING YOUR PERT
  • Brief Overview & PERT Partners
  • Experiences from PERT in Rural/Community
  • What's Next? PERT 2.0: The Future
  • PERT After Hospital - Fast Program
  • PERT After Hospital

WORKSHOP D: PE CENTERS OF EXCELLENCE™
  • Overview of PE Centers of Excellence™
  • Value Proposition of PERT / How to Sell this to Your Health System
  • Discussion and Q & A

SESSION 6: Oral Abstracts
  • Abstract 1
  • Abstract 2
  • Abstract 3
  • Q & A
SESSION 7: PE Game Show

POSTER SESSION & COCKTAIL RECEPTION
Agenda: Friday, September 13
BREAKFAST & INDUSTRY SATELLITE SESSIONS

SESSION 8: Welcome and Keynote

SESSION 9: Live PERT Case

SESSION 10: Clinical Trials : Devices & Data, All You Need to Know
  • IDE over the Line: Completed Single arm trials (FLARE, EXTRACT, RESCUE, APEX)
  • Single arm studies: More devices and evidence on the way (Symphony, Enguld, Aventus, Akura, Innova)
  • Trials in the pipeline
  • Post Market Trials: FLAME, STRIKE PE, RESCUE-PE and RAPID-PE
  • RCTs 1: HI-PEITHO, PEITHO 3, PE-TRACT
  • RCTs 2: STORM-PE, PEERLESS, PEERLESS 2
  • Panel Discussion: Where the Data Is Now and Where It is Going
SESSION 11: Post-PE Care
  • Pathophysiology of Dyspnea after PE
  • Brief survey of available tests and is there any data– 10 min (CT, Vq, RHC, TTE)
  • Cases
  • Anticoagulation Considerations
  • Q & A
LUNCH AND INDUSTRY SATELLITE SESSIONS

SESSION 12: CTED/CTEPH MONITORING
  • RPVO
  • CTE__: Complications of RPVO other than CTEPH
  • PTE
  • BPA
  • Medical management
  • Panel Discussion
WORKSHOP E: NOT QUITE CTEPH: WHAT TO DO
  • Defining the Problem. Who are we talking about?
  • CTEPD: Watch or Intervene
  • BPA in CTEPD: What is the Experience
  • What to follow after Intervention
  • Q & A
WORKSHOP F: ARTIFICIAL INTELLIGENCE
  • Acute Diagnosis and Triage
  • Chatbots and Other Language Models
  • Longitudinal Patient Care Coordination
  • Future Directions / Research
  • Panel
WORKSHOP G: MCS BEYOND THE BASICS
  • Case Challenge
  • Interrupting the death spiral of acute PE- How does MCS address pathophysiology
  • Proactive or reactive…When to initiate MCS?
  • The "Art" of Cannulation
  • When to extirpate and when to decannulate
  • Roundtable discussion & Q & A with additional case challenges
SESSION 13: Best Papers of the Year

10th Anniversary Gala
Agenda: Saturday, September 14
SESSION 14: Welcome

SESSION 15: Meet the Experts
  • PERT from the exPERTs…Controversies and Case Challenges
  • Session 15: Challenge the Experts: What is the Right Answer
  • Challenge Our Panel
  • How We Do It
  • Key Controversies and Case Challenges
SESSION 16: Medical Management
  • Anticoagulation
  • Anticoagulation Duration
  • Thrombophilia pro/con
  • Thrombophilia pro/con
  • In or Out-Patient Care
  • Discussion/Panel/ Q & A
SESSION 17: Special Populations
  • Understanding Pulmonary Embolism in Women
  • Clotting Conundrum: Pulmonary Embolism and Sickle Cell Disease
  • More than a SOB Story: Impact of Pulmonary Embolism in Children
  • Beyond the Surface: Pulmonary Embolism in Obese Individuals
  • Q & A, Discussion
SESSION 18: Greatest Saves & Toughest Complications
  • Case 1
  • Case 2
  • Case 3
  • Q & A